XML 38 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss per Common Share (Tables)
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:

 

March 31,

 

 

2025

 

 

2024*

 

Stock options outstanding

 

12,228,168

 

 

 

6,892,951

 

Restricted stock units outstanding

 

2,421,954

 

 

 

3,110,597

 

Shares reserved for future issuance

 

5,382,829

 

 

 

1,649,038

 

Apexigen replacement warrants

 

1,003,191

 

 

 

1,003,191

 

Employee stock purchase plan

 

653,777

 

 

 

675,485

 

Total

 

21,689,919

 

 

 

13,331,262

 

*Pre-Funded Warrant Shares of 1,611,215 shares are included in the computation of basic and diluted net loss per common share for the three months ended March 31, 2024 as the Pre-Funded Warrants were issuable for nominal consideration.